Navigation Links
Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
Date:1/23/2008

TORONTO, Jan. 23 /PRNewswire/ - Dalton Medicinal Chemistry Partners, the Medicinal Chemistry arm of Dalton Pharma Services, announces that it has achieved another targeted milestone in its Medicinal Chemistry agreement with Boehringer Ingelheim (Canada) Ltd.

Dalton Medicinal Chemistry Partners is utilizing their medicinal chemistry expertise to design and synthesize novel compounds against an antiviral target selected by Boehringer Ingelheim (Canada) Ltd. Peter Pekos, President of Dalton Pharma Services, said: "We are pleased to achieve this additional milestone in our exciting partnership with Boehringer Ingelheim (Canada) Ltd. It is a pleasure working with the talented team at BI."

About Dalton

Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry and analytical services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing and sterile filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its state of the art cGMP facilities, Dalton produces active pharmaceutical ingredients (API) at the gram or kilogram scale. Dalton carries out sterile fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton's analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients.


'/>"/>
SOURCE Dalton Pharma Services
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
2. BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
5. Argonne scientist to give the plenary talk at Royal Society of Chemistry meeting on nanoalloys
6. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
7. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
8. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
9. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
10. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
11. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... , Feb. 28, 2017 Sangamo ... genome editing, today reported its fourth quarter and ... "Early this year we rebranded our ... clinical development of genomic therapies using our industry ... gene regulation and cell therapy," said Sandy ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... cold-pressed fruit and vegetable drink brand is now available on Amazon.com ... LLC to manufacture and distribute the Vegesentials line of juices throughout North ...
(Date:2/27/2017)... , Feb. 27, 2017 AcelRx Pharmaceuticals, ... on the development and commercialization of innovative therapies ... today the U.S. Food and Drug Administration (FDA) ... under section 505(b)(2) for DSUVIA™ (formerly ARX-04) (sufentanil ... patients with moderate-to-severe acute pain in a medically ...
(Date:2/27/2017)... -- Fluxion Biosciences announced today that Genetracer Biotech of ... as a Certified Service Provider for Fluxion,s IsoFlux CTC ... in Genetracer Biotech,s novel liquid biopsy workflows for detection ... plans to move to other cancers as additional assays ... to isolate, recover, and analyze CTCs (circulating tumor cells) ...
Breaking Biology Technology:
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:2/1/2017)... February 1, 2017 IDTechEx Research, a leading ... technology, announces the availability of a new report, Sensors for ... Continue Reading ... ... collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and ...
(Date:1/26/2017)...  Crossmatch, a leading provider of security and identity ... combatting fraud, waste and abuse in assistance operations around ... on Disaster Relief conference in Panama City ... and foreign assistance organizations throughout Latin America ... a largely unacknowledged problem in the foreign assistance and ...
Breaking Biology News(10 mins):